While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

The Chinese AI startup plans to go public in Hong Kong, positioning itself as a rival to OpenAI. MiniMax aims to raise at least 3.83 billion Hong Kong dollars ($492 million) by selling roughly 25.4 ...

What if the next big leap in AI wasn’t locked behind corporate paywalls but was instead freely available for anyone to explore, adapt, and innovate with? That’s exactly the promise of MiniMax M2.1, ...

MiniMax, a Chinese rival to OpenAI (OPENAI), unveiled its new M2.1 artificial intelligence model on Tuesday, stating it is “significantly enhanced” over previous offerings. Some of the highlights of ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Aoostar released an updated teaser image of its AMD Ryzen Strix Halo-powered mini PC, the Aoostar Nex395, with a much different design than the original. The new design looks much smoother and more ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...